Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report.
Flávia Amaral DuarteLeonardo Brand RodriguesFlávia Rocha PaesPaulo Henrique Costa DinizHelena Flávia Cuba de Almada LimaPublished in: BMC pulmonary medicine (2021)
This case suggests that alectinib, even belonging to the same drug class, could be used as an alternative agent when crizotinib is the etiology of liver damage, but more robust evidence has awaited.